New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|August 1, 2008
The American Journal of Managed Care
- August 2008
- Volume 14
- Issue 8
Participant Disclosure (Am J Manag Care. 2008;14[suppl 8]:S241-S268)
Advertisement
Our July 2008 supplement on Biologics and Benefit Design, funded by Amgen Inc, (Am J Manag Care. 2008;14[suppl 8]:S241-S268), included an error of omission on the Participant Disclosures page.
The following disclosures for Robert Berglund should have been noted on S244:
Robert Berglund
Honoraria, Amgen Inc
Articles in this issue
about 18 years ago
A Meta-analysis Update: Percutaneous Coronary Interventionsabout 18 years ago
Medicare HMO Impact on Utilization at the End of Lifeabout 18 years ago
Flunking Asthma? When HEDIS Takes the ACTAdvertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5